Literature DB >> 556989

Tolerance of haloperidol catalepsy.

C Ezrin-Waters, P Seeman.   

Abstract

Haloperidol (0.75 and 1.5 mg/kg p.o.) was administered daily for 16 days to male Wistar rats. The animals received an acute injection of haloperidol (0.5-2.0 mg/kg i.p. or 1.0-4.0 mg/kg p.o.) and catalepsy was measured. After 16 days on haloperidol, all animals became tolerant to the drug, exhibiting decreased cataleptic response to haloperidol; the intensity of catalepsy returned to normal after an additional 16 days abstinence from the drug. In addition, a group of animals treated and tested daily for catalepsy demonstrated that the time course of tolerance development to haloperidol was biphasic, with a rapid phase (T1/2 = 2.5 days) and a slower phase (T1/2 = 5.5 days).

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 556989     DOI: 10.1016/0014-2999(77)90325-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.

Authors:  C J de Graaf; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

2.  Chronic low-dose haloperidol effects on self-stimulation rate-intensity functions.

Authors:  M R Lynch; R J Carey
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

Review 3.  Dopaminergic supersensitivity after neuroleptics: time-course and specificity.

Authors:  P Muller; P Seeman
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

4.  Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.

Authors:  J Lappalainen; J Hietala; E Syvälahti
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 5.  Role of nitric oxide on motor behavior.

Authors:  E A Del Bel; F S Guimarães; M Bermúdez-Echeverry; M Z Gomes; A Schiaveto-de-souza; F E Padovan-Neto; V Tumas; A P Barion-Cavalcanti; M Lazzarini; L P Nucci-da-Silva; D de Paula-Souza
Journal:  Cell Mol Neurobiol       Date:  2005-03       Impact factor: 5.046

6.  Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics.

Authors:  A S Undie; E Friedman
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 7.  Neurobehavioral tests in single- and repeated-dose toxicity studies in small rodents.

Authors:  S Alder; G Zbinden
Journal:  Arch Toxicol       Date:  1983-09       Impact factor: 5.153

8.  Treatment schedule as a determinant of the development of tolerance to haloperidol.

Authors:  R J Carey; J DeVeaugh-Geiss
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Haloperidol Selectively Remodels Striatal Indirect Pathway Circuits.

Authors:  Luke E Sebel; Steven M Graves; C Savio Chan; D James Surmeier
Journal:  Neuropsychopharmacology       Date:  2016-08-31       Impact factor: 7.853

10.  Transient supression by stress of haloperidol induced catalepsy by the activation of the adrenal medulla.

Authors:  O P Yntema; J Korf
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.